3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
12
Endocrine
1
CNS
1
Breast
1
Conditions
von Hippel-Lindau Disease
1
Pheochromocytoma
1
Paraganglioma
1
Adenoma, Islet Cell
1
Interventions
Specimen Handling
13
Magnetic Resonance Spectroscopy
13
lutetium Lu 177 dotatate
10
cabozantinib
6
Nivolumab
5
X-Rays
4
Ipilimumab
4
Cisplatin
4
pembrolizumab
3
olaparib
3
fludarabine
3
Phantoms, Imaging
3
Everolimus
3
Etoposide
3
Cyclophosphamide
3
Carboplatin
3
CTLA-4 Antigen
3
gallium Ga 68 dotatate
2
fluorodopa F 18
2
aldesleukin
2
Temozolomide
2
Lutetium-177
2
Lutetium
2
Irinotecan
2
Fluorodeoxyglucose F18
2
3-aminopyridine-2-carboxaldehyde thiosemicarbazone
2
trametinib
1
tipifarnib
1
sodium thiosulfate
1
selpercatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
belzutifan
×
Endocrine
×
30 days
×
Clear all
NCT04924075
2026-05-28
MK-6482-015
Merck Sharp & Dohme LLC
Phase 2
Recruiting
322 enrolled
1 FDA